Skip to main content
Erschienen in: Journal of Endocrinological Investigation 8/2014

01.08.2014 | Original Article

Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis

verfasst von: Mazhar Müslüm Tuna, Narin Nasıroğlu Imga, Berçem Ayçiçek Doğan, Fatma Meriç Yılmaz, Canan Topçuoğlu, Gülhan Akbaba, Dilek Berker, Serdar Güler

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors. The aim of this study was to investigate plasma adiponectin, leptin, resistin, homocysteine, high sensitive C-reactive protein levels, and carotid intima media thickness (CIMT) in patients with non-functioning AI (NFAI).

Materials and methods

This study included data from 28 patients with NFAI (Group 1) and 41 controls (Group 2). Of the patients, 50 were female and 19 were male, and the mean age was 46.7 (range 37–65) years.

Results

There were no significant differences between Group 1 and 2 in terms of age, sex, or BMI. Hypertension prevalence was significantly higher in the NFAI group than in the control group (p = 0.01). Both groups had similar lipid, blood glucose, homocysteine, uric acid, high-sensitivity CRP levels. Adiponectin, leptin, and resistin levels were similar in both groups. CIMTs were significantly higher in the NFAI group.

Conclusion

There is increasing evidence that several cardiometabolic risk factors occur with higher prevalence in non-functioning adrenal incidentaloma patients compared to age-matched healthy subjects. In our study, hypertension prevalence and CIMT were higher in the NFAI group. Serum adipokine levels were similar for both groups.
Literatur
1.
Zurück zum Zitat Young WF Jr (2007) Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356:601–610PubMedCrossRef Young WF Jr (2007) Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356:601–610PubMedCrossRef
2.
Zurück zum Zitat Barzon L, Sonino N, Fallo F et al (2003) Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273–285PubMedCrossRef Barzon L, Sonino N, Fallo F et al (2003) Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273–285PubMedCrossRef
3.
Zurück zum Zitat Mansmann G, Lau J, Balk E et al (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25:309–340PubMedCrossRef Mansmann G, Lau J, Balk E et al (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25:309–340PubMedCrossRef
4.
Zurück zum Zitat Mantero F, Arnaldi G (1999) Investigation protocol: adrenal enlargement. Clin Endocrinol (Oxf) 50:141–146CrossRef Mantero F, Arnaldi G (1999) Investigation protocol: adrenal enlargement. Clin Endocrinol (Oxf) 50:141–146CrossRef
5.
Zurück zum Zitat Morelli V et al (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99:827–834PubMed Morelli V et al (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99:827–834PubMed
6.
Zurück zum Zitat Reincke M, Fassnacht M, Vath S, Mora P, Allolio B (1996) Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22:757–761PubMed Reincke M, Fassnacht M, Vath S, Mora P, Allolio B (1996) Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22:757–761PubMed
7.
Zurück zum Zitat Chiodini I, Morelli V et al (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95(6):2736–2745PubMedCrossRef Chiodini I, Morelli V et al (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95(6):2736–2745PubMedCrossRef
8.
Zurück zum Zitat Yenigün M, Türker T, Ataoğlu HE et al (2005) From obesity to diabetes. Haseki Tıp Bülteni 43:1–12 Yenigün M, Türker T, Ataoğlu HE et al (2005) From obesity to diabetes. Haseki Tıp Bülteni 43:1–12
9.
Zurück zum Zitat Steppan CM, Lazar MA (2002) Rezistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13:18–23PubMedCrossRef Steppan CM, Lazar MA (2002) Rezistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13:18–23PubMedCrossRef
10.
Zurück zum Zitat Mantero F, Terzolo M, Arnaldi G et al (2000) A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab 85:637–644PubMed Mantero F, Terzolo M, Arnaldi G et al (2000) A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab 85:637–644PubMed
11.
Zurück zum Zitat Reincke M, Nieke J, Krestin GP et al (1992) Preclinical Cushing’s syndrome in adrenal incidentalomas: comparison with adrenal Cushing’s syndrome. J Clin Endocrinol Metab 75(3):826–832PubMed Reincke M, Nieke J, Krestin GP et al (1992) Preclinical Cushing’s syndrome in adrenal incidentalomas: comparison with adrenal Cushing’s syndrome. J Clin Endocrinol Metab 75(3):826–832PubMed
12.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
13.
Zurück zum Zitat Beşir FH, Yazgan S, Celbek G, Aydın M et al (2012) Normal values correlates’ of carotid intima- media thickness and affecting parameters in healthy adults. Anadolu Kardiyol Derg 12(5):427–433PubMed Beşir FH, Yazgan S, Celbek G, Aydın M et al (2012) Normal values correlates’ of carotid intima- media thickness and affecting parameters in healthy adults. Anadolu Kardiyol Derg 12(5):427–433PubMed
14.
Zurück zum Zitat Zhang W, Tang ZY, Wang WQ et al (2006) Metabolic syndrome in patients with adrenocortical adenoma. Zhonghua Yi Xue Za Zhi 86:3397–3400PubMed Zhang W, Tang ZY, Wang WQ et al (2006) Metabolic syndrome in patients with adrenocortical adenoma. Zhonghua Yi Xue Za Zhi 86:3397–3400PubMed
15.
Zurück zum Zitat Wagnerova H, Dudasova D, Lazurova I (2009) Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma 56:521–525PubMedCrossRef Wagnerova H, Dudasova D, Lazurova I (2009) Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma 56:521–525PubMedCrossRef
16.
Zurück zum Zitat Comlekci A, Yener S, Ertilav S et al (2010) Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 37(1):40–46PubMedCrossRef Comlekci A, Yener S, Ertilav S et al (2010) Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 37(1):40–46PubMedCrossRef
17.
Zurück zum Zitat Garrapa G, Paola P, Gıorgıo A et al (2001) Body composition in adrenal ıncidentaloma. J Clin Endocrinol Metab 86(11):5301–5306PubMed Garrapa G, Paola P, Gıorgıo A et al (2001) Body composition in adrenal ıncidentaloma. J Clin Endocrinol Metab 86(11):5301–5306PubMed
18.
Zurück zum Zitat Kastelein JJ, de Groot E (2008) Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 29:849–858PubMedCrossRef Kastelein JJ, de Groot E (2008) Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 29:849–858PubMedCrossRef
19.
Zurück zum Zitat Yener S, Genc S, Akinci B et al (2009) Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine 35(3):365–370PubMedCrossRef Yener S, Genc S, Akinci B et al (2009) Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine 35(3):365–370PubMedCrossRef
20.
Zurück zum Zitat Ermetici F, Malavazos AE, Corbetta S et al (2007) Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 56(5):686–692PubMedCrossRef Ermetici F, Malavazos AE, Corbetta S et al (2007) Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 56(5):686–692PubMedCrossRef
21.
Zurück zum Zitat Terzolo M, Pia A, Alı A et al (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998–1003PubMedCrossRef Terzolo M, Pia A, Alı A et al (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998–1003PubMedCrossRef
22.
Zurück zum Zitat Harman E, Karadeniz M, Biray C et al (2009) The relation of adiponectin and tumor necrosis factor alpha levels between endothelial nitric oxide synthase, angiotensin-converting enzyme, transforming growth factor beta, and tumor necrosis factor alpha gene polymorphism in adrenal incidentalomas. J Endocrinol Invest 32(11):881–888PubMed Harman E, Karadeniz M, Biray C et al (2009) The relation of adiponectin and tumor necrosis factor alpha levels between endothelial nitric oxide synthase, angiotensin-converting enzyme, transforming growth factor beta, and tumor necrosis factor alpha gene polymorphism in adrenal incidentalomas. J Endocrinol Invest 32(11):881–888PubMed
23.
Zurück zum Zitat Lazúrová I, Spišáková D, Wagnerová H et al (2011) Clinically silent adrenal adenomas—their relation to the metabolic syndrome and to GNB3 C825T gene polymorphism. Wien Klin Wochenschr 123(19–20):618–622PubMedCrossRef Lazúrová I, Spišáková D, Wagnerová H et al (2011) Clinically silent adrenal adenomas—their relation to the metabolic syndrome and to GNB3 C825T gene polymorphism. Wien Klin Wochenschr 123(19–20):618–622PubMedCrossRef
Metadaten
Titel
Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis
verfasst von
Mazhar Müslüm Tuna
Narin Nasıroğlu Imga
Berçem Ayçiçek Doğan
Fatma Meriç Yılmaz
Canan Topçuoğlu
Gülhan Akbaba
Dilek Berker
Serdar Güler
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 8/2014
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-014-0106-5

Weitere Artikel der Ausgabe 8/2014

Journal of Endocrinological Investigation 8/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.